U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled to $3.57 billion in the third quarter. Meanwhile, revenue ...
Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.
Eli Lilly's GLP-1 sales are rising at an unexpectedly strong pace, prompting its arch rival to make a surprising bid for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback